Cognition Therapeutics Reports Third Quarter Financial Results and Company Highlights
November 18, 2021 08:00 ET
|
Cognition Therapeutics, Inc.
PURCHASE, N.Y., Nov. 18, 2021 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (Nasdaq: CGTX), a clinical-stage biopharmaceutical company engaged in the discovery and development of innovative,...
Cognition Therapeutics Announces Closing of Full Exercise of Underwriters’ Option to Purchase Additional Shares in connection with Initial Public Offering
November 15, 2021 07:30 ET
|
Cognition Therapeutics, Inc.
PURCHASE, N.Y., Nov. 15, 2021 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. [Nasdaq: CGTX], a clinical-stage biopharmaceutical company engaged in the discovery and development of innovative,...
Cognition Therapeutics Adds Public Company Financial and Operational Expertise to Board of Directors with Appointment of Ellen B. Richstone
November 03, 2021 08:00 ET
|
Cognition Therapeutics, Inc.
PURCHASE, N.Y., Nov. 03, 2021 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (Nasdaq: CGTX), a clinical-stage biopharmaceutical company engaged in the discovery and development of innovative,...
Cognition Therapeutics Announces Pricing of Upsized Initial Public Offering
October 08, 2021 07:30 ET
|
Cognition Therapeutics, Inc.
PURCHASE, N.Y., Oct. 08, 2021 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., a clinical-stage biopharmaceutical company engaged in the discovery and development of innovative, small molecule...
Cognition Therapeutics Announces Launch of its Initial Public Offering
October 04, 2021 07:54 ET
|
Cognition Therapeutics, Inc.
PURCHASE, N.Y., Oct. 04, 2021 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., a clinical-stage biopharmaceutical company engaged in the discovery and development of innovative, small molecule...
Cognition Therapeutics Announces Election of Jack Khattar Chairman of the Board
April 20, 2021 11:31 ET
|
Cognition Therapeutics, Inc.
Pittsburgh, April 20, 2021 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., a clinical stage neuroscience company developing drugs that treat degenerative disorders by regulating cellular damage...
Cognition Therapeutics to Present Corporate and Clinical Update at H.C. Wainwright Global Life Sciences Conference
March 03, 2021 08:01 ET
|
Cognition Therapeutics, Inc.
New York, NY, March 03, 2021 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., a clinical stage neuroscience company developing drugs that treat neurodegenerative disorders by regulating cellular...
Cognition Therapeutics Publishes Biomarker Findings from Clinical Study of CT1812 Supporting Positive Impact on Synapse Biology
February 10, 2021 08:00 ET
|
Cognition Therapeutics, Inc.
Pittsburgh, Feb. 10, 2021 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., a clinical stage neuroscience company developing drugs that treat neurodegenerative disorders by regulating cellular...
Cognition Therapeutics Publishes Evidence Identifying Receptor Integral in Parkinson’s Disease Pathology
February 01, 2021 08:00 ET
|
Cognition Therapeutics, Inc.
PITTSBURGH, Feb. 01, 2021 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., a clinical stage neuroscience company developing drugs that treat neurodegenerative disorders by regulating cellular...
Cognition Therapeutics Reviews 2020 Accomplishments and Provides 2021 Guidance
January 05, 2021 09:44 ET
|
Cognition Therapeutics, Inc.
Pittsburgh, Jan. 05, 2021 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., a clinical stage neuroscience company developing drugs that treat neurodegenerative disorders by regulating cellular...